Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.51 |
| ▸ | APLNR | P35414 | 2/20 | 0.49 |
| ▸ | TAS2R14 | Q9NYV8 | 5/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22553433 | 0.85 | APLNR (0.46) | HRH3APLNRTAS2R14CHRM2PTGES | |
| SCHEMBL20189329 | 0.83 | APLNR (0.44) | HRH3APLNRTAS2R14PTGESKCNH2 | |
| SCHEMBL18246510 | 0.83 | APLNR (0.44) | HRH3APLNRTAS2R14PTGESKCNH2 | |
| SCHEMBL18246509 | 0.83 | APLNR (0.44) | HRH3APLNRTAS2R14PTGESKCNH2 | |
| SCHEMBL22553457 | 0.82 | APLNR (0.51) | APLNRTAS2R14PTGESMAPTPKM | |
| SCHEMBL22553416 | 0.80 | HRH3 (0.56) | HRH3APLNRMAPT | |
| SCHEMBL20187955 | 0.78 | HCRTR1 (0.44) | HRH3APLNRTAS2R14PTGES | |
| SCHEMBL18245832 | 0.78 | APLNR (0.44) | HRH3APLNRTAS2R14PTGESKCNH2 | |
| SCHEMBL20187951 | 0.78 | HCRTR1 (0.44) | HRH3APLNRTAS2R14PTGES | |
| SCHEMBL18245834 | 0.78 | APLNR (0.44) | HRH3APLNRTAS2R14PTGESKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773058-B2 | Sulfonamide carboxamide compounds | INFLAZOME LIMITED (IE) | 2023-10-03 | — | — | US | disclosed |
| US-11773058-B2 | Sulfonamide carboxamide compounds | INFLAZOME LIMITED (IE) | 2023-10-03 | — | — | US | disclosed |
| US-20200331850-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773058-B2 | Sulfonamide carboxamide compounds | NLRP3, NOD1, NLRP1 | HRH3 499/4885APLNR 1240/4885TAS2R14 345/4885 |
| US-20200331850-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | NLRP3, NOD1, NLRP1 | HRH3 639/4885APLNR 1280/4885TAS2R14 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.